Nodora Jesse N, Gilbert Jacqueline A, Martinez Maria Elena, Arslan Waqas, Reyes Trevin, Dover John A, Ramos Gilbert M, Komenaka Ian G, Hitchon Hebert D, Komenaka Ian K
University of California San Diego, San Diego, CA, USA.
Morehouse School of Medicine, Atlanta, GA, USA.
Cancer Causes Control. 2025 Mar;36(3):309-319. doi: 10.1007/s10552-024-01935-8. Epub 2024 Nov 26.
A significant proportion of many populations remain uninsured. The aim of the study was to assess differences in breast cancer outcomes before and after the implementation of an innovative approach to the multidisciplinary treatment of uninsured breast cancer patients.
Retrospective review was performed of patients seen at a safety net hospital from January 2000 to December 2020. Beginning July 2006, an innovative approach was implemented to lower patient costs and facilitate care of uninsured patients.
The study included 1,797 patients, 661 patients before the changes (BCS), and 1136 patients after implementation of the new cost saving approach (ACS). The mean age was 53 years. The majority were uninsured (56%) or insured by Medicaid (31%). Only 18% underwent screening mammography. The ACS group had a higher rate of breast conservation (75% vs 47%, p < 0.001). A higher percentage of the ACS group received adjuvant therapy: Chemotherapy (91% vs 70%, p < 0.001), Radiation therapy (91% vs 70%, p < 0.001), and initiated endocrine therapy (87% vs 67%, p < 0.001). After follow-up of 8 years, these changes resulted in lower ipsilateral breast tumor recurrence (2% vs 16%, p < 0.001) and chest wall recurrence (5% versus 8%) and improvement in overall survival (90% vs 81%, p < 0.001).
Peer-reviewed literature is replete of studies documenting disparities in breast cancer treatment. The current study describes a successful cost-limiting method which takes advantage of existing financial assistance programs to improve care in uninsured patients.
许多人群中有相当一部分人仍未参保。本研究的目的是评估在实施一种创新的多学科治疗未参保乳腺癌患者的方法前后,乳腺癌治疗结果的差异。
对2000年1月至2020年12月在一家安全网医院就诊的患者进行回顾性研究。从2006年7月开始,实施了一种创新方法以降低患者成本并促进未参保患者的治疗。
该研究纳入了1797例患者,其中661例在变革前(BCS组),1136例在实施新的成本节约方法后(ACS组)。平均年龄为53岁。大多数人未参保(56%)或由医疗补助计划承保(31%)。只有18%的人接受了乳腺钼靶筛查。ACS组保乳率更高(75%对47%,p<0.001)。ACS组接受辅助治疗的比例更高:化疗(91%对70%,p<0.001)、放疗(91%对70%,p<0.001)以及开始内分泌治疗(87%对67%,p<0.001)。经过8年的随访,这些变化导致同侧乳腺肿瘤复发率降低(2%对16%,p<0.001)、胸壁复发率降低(5%对8%)以及总生存率提高(90%对81%,p<0.001)。
同行评审文献中有大量研究记录了乳腺癌治疗中的差异。本研究描述了一种成功的成本限制方法,该方法利用现有的财政援助计划来改善未参保患者的治疗。